Pathologic Function – Page 5

FDA Rejects Full Approval for AstraZeneca’s Andexxa Amid Safety Concerns

9 months ago talkbio0Tagged Andexxa, Approved, AstraZeneca, concerns, F10 wt Allele, Hemorrhage, inhibitors, reversal agent, Safety, United States Food and Drug Administration

Andexxa, AstraZeneca, FDA, full approval, safety concerns, bleeding reversal agent, FXa inhibitors

PureTech’s Deupirfenidone (LYT-100) Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Phase 2b Trial

9 months ago talkbio0Tagged decline, Fibrosis, High, Idiopathic Pulmonary Fibrosis, Lung, LYT 100, Phase 2b Trial, pirfenidone, PureTech Health, Respiratory physiology

PureTech Health, Deupirfenidone (LYT-100), Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Phase 2b Trial, ELEVATE IPF Trial, Pulmonary Fibrosis Treatment

GSK and Relation Therapeutics Collaborate on Fibrosis and Osteoarthritis Research with AI-Driven Approach

9 months ago talkbio0Tagged Aortic Valve Insufficiency, Degenerative polyarthritis, Drug Discovery, Fibrosis, Machine Learning, Relative (related person), SmithKline Beecham

Relation Therapeutics, GSK, Fibrosis, Osteoarthritis, AI in drug discovery, Machine learning in biotech

Neurogene’s Rett Syndrome Trial Halted After Patient Death Linked to High-Dose Gene Therapy

10 months ago talkbio0Tagged AAVS1 gene, Clinical Trials, Complication, gene therapy, high-dose, Neurogene, Rett Syndrome

Neurogene, Rett syndrome, gene therapy, AAV, clinical trial, patient death, high-dose complications

Enveda Secures $130 Million in Funding for Innovative Therapies in Inflammation, Obesity, and Beyond

10 months ago talkbio0Tagged Drug Development, Enveda, I&I, Inflammation, Microsoft-backed, Obesity, Pharma

Enveda, Microsoft-backed, $130M funding, Inflammation & Immunology (I&I), obesity, biotech, pharma, drug development

FDA Raises Safety Concerns Over AstraZeneca’s Andexxa Ahead of Advisory Committee Meeting

10 months ago talkbio0Tagged Advisory Committees, Andexxa, AstraZeneca, concerns, Hemorrhage, reversal agent, Safety, United States Food and Drug Administration

AstraZeneca, Andexxa, FDA, safety concerns, bleeding reversal agent, advisory committee meeting

Dupixent (Dupilumab) Advances Towards FDA Approval for Chronic Spontaneous Urticaria (CSU) in 2025

10 months ago talkbio0Tagged Biologic Medicine, Chronic Spontaneous Urticaria, dupilumab, Dupixent, Inflammation, Regeneron, Review [Publication Type], sanofi, United States Food and Drug Administration

Dupixent, Dupilumab, Chronic Spontaneous Urticaria (CSU), FDA Review, Sanofi, Regeneron, Biologic Medicine, Type 2 Inflammation, H1 Antihistamines

Sinaptica’s Neuromodulation Therapy Demonstrates 44% Reduction in Alzheimer’s Disease Progression

11 months ago talkbio0Tagged Alzheimer 's disease, Default Mode Network, Disease Progression, neuromodulation therapy, Non-invasive therapy, Personalized Treatment, Sinaptica, Stimulation procedure, Structure of precuneus

Sinaptica Therapeutics, Neuromodulation therapy, Alzheimer’s disease, Disease progression reduction, Personalized treatment, Non-invasive therapy, Default Mode Network (DMN), Precuneus stimulation